{"node_1":{"0":"abx","1":"abx","2":"abx","3":"abx","4":"abx","5":"abx","6":"abx","7":"abx","8":"abx","9":"advanced malignancy","10":"alpha-synuclein","11":"alpha-synuclein","12":"alpha-synuclein autophagy-lysosome degradation pathways","13":"ambroxol (abx)","14":"ambroxol (abx)","15":"ambroxol (abx)","16":"ambroxol in new and early dementia with lewy bodies (aneed)","17":"aneed","18":"aneed","19":"aneed","20":"aneed study","21":"antibiotic abx","22":"antibiotic abx","23":"antibiotic abx","24":"antibiotic abx","25":"antibiotic abx","26":"antibiotic abx","27":"antiparkinsonian drugs","28":"antiparkinsonian medications","29":"caregiver","30":"caregiver","31":"chaperone-mediated autophagy (cma)","32":"chaperone-mediated autophagy (cma)","33":"chaperone-mediated autophagy (cma)","34":"clinical outcome measures","35":"cma","36":"degradation pathways","37":"dementia medications","38":"dementia medications","39":"dementia with lewy bodies","40":"dementia with lewy bodies","41":"dementia with lewy bodies (dlb)","42":"dementia with lewy bodies (dlb)","43":"dementia with lewy bodies (dlb)","44":"dementia with lewy bodies (dlb)","45":"digital cerebrospinal fluid (csf) biomarkers","46":"double-blind","47":"exclusion criteria","48":"exclusion criteria","49":"exclusion criteria","50":"gba gene mutations","51":"gba gene mutations","52":"gba gene mutations","53":"gba mutations","54":"gcase activity","55":"gcase dysfunction","56":"gcase enzyme activity","57":"gcase enzyme levels","58":"genome-wide association study (gwas)","59":"glucocerebrosidase","60":"human cells","61":"in vivo experiments","62":"inclusion criteria","63":"informed consent capacity","64":"major cardiovascular events","65":"mckeith criteria","66":"mild cognitive impairment due to dlb (mci-dlb)","67":"mini-mental state examination (mmse) score","68":"multicenter clinical trial","69":"parallel group design","70":"parkinson's disease (pd)","71":"patients","72":"placebo-controlled","73":"population studies","74":"preclinical evidence","75":"preclinical trials","76":"randomized","77":"rationale for treatment","78":"reduced alpha-synuclein clearance","79":"reduced alpha-synuclein clearance","80":"sensitivity to antibiotics","81":"toxic alpha-synuclein (as) species","82":"traditional cerebrospinal fluid (csf) biomarkers"},"node_2":{"0":"cerebrospinal fluid (csf)","1":"dementia with lewy bodies (dlb)","2":"effects","3":"glucocerebrosidase (gcase) activity","4":"lysosomal alpha-synuclein clearance","5":"mechanism of action","6":"synucleinopathies","7":"toxic alpha-synuclein (as) species","8":"treatment rationale","9":"exclusion criteria","10":"dementia with lewy bodies","11":"pathological deposition","12":"gcase enzyme activity","13":"dementia with lewy bodies (dlb)","14":"modifying drug","15":"patients","16":"clinical study","17":"effects","18":"safety","19":"tolerability","20":"clinical trial","21":"clinical trial","22":"efficacy profile","23":"patients with dlb","24":"safety profile","25":"synucleinopathies","26":"tolerability profile","27":"study participants","28":"dosage","29":"frequency of contact","30":"participant","31":"abx","32":"pathological alpha-synuclein","33":"pathological alpha-synuclein (as) depositions","34":"treatment efficacy","35":"enhancement of clearance","36":"ambroxol (abx)","37":"dosage","38":"study participants","39":"alpha-synuclein","40":"disease-modifying pharmacological treatment","41":"dementia","42":"diagnosis","43":"gba gene mutations","44":"synucleinopathies","45":"treatment efficacy","46":"clinical trial","47":"medical conditions","48":"psychiatric disorders","49":"surgical conditions","50":"dementia with lewy bodies (dlb)","51":"parkinson's disease (pd)","52":"risk of developing pd","53":"dementia with lewy bodies","54":"alpha-synuclein metabolism","55":"gba gene mutations","56":"ambroxol (abx)","57":"ambroxol (abx)","58":"gba gene mutations","59":"gcase dysfunction","60":"glucocerebrosidase (gcase) activity","61":"gcase enzyme activity","62":"study participants","63":"participant","64":"initial visit","65":"diagnosis","66":"diagnosis","67":"screening","68":"phase iia","69":"clinical trial","70":"risk of developing","71":"dementia with lewy bodies (dlb)","72":"clinical trial","73":"gba mutations","74":"clinical evidence","75":"abx","76":"clinical trial","77":"abx","78":"autophagic pathways","79":"endolysosomal pathways","80":"exclusion criteria","81":"pathological alpha-synuclein (as) depositions","82":"treatment efficacy"},"edge_list":{"0":"penetrates into","1":"is a modifying treatment in","2":"show","3":"enhances effect on","4":"enhances","5":"has unique mechanism on","6":"is tested in models of","7":"reduces concentration of","8":"is established by","9":"is part of","10":"is a hallmark of","11":"causes","12":"enhanced by","13":"is a modifying drug for","14":"is a type of","15":"is administered to","16":"is a","17":"investigates","18":"investigates","19":"investigates","20":"is an","21":"is part of","22":"evaluates","23":"is tested on","24":"evaluates","25":"is used for treating","26":"evaluates","27":"are used by","28":"are prescribed in","29":"contacts","30":"has contact with","31":"is a potential treatment for","32":"may reduce","33":"may reduce","34":"measures","35":"may lead to","36":"may affect","37":"are prescribed in","38":"are used by","39":"is characterized by","40":"has no available","41":"is a type of","42":"is a type of","43":"show higher incidence of","44":"is a type of","45":"measures","46":"is a characteristic of","47":"includes","48":"includes","49":"includes","50":"are more prevalent in","51":"are associated with a higher incidence in","52":"increases the","53":"are associated with","54":"is associated with","55":"is caused by","56":"may increase","57":"may increase","58":"confirms correlation with","59":"is related to","60":"is affected by","61":"demonstrate effects on","62":"applies to","63":"is required from","64":"occurred prior to","65":"establishes","66":"is a type of","67":"is a measure in","68":"is a type of","69":"is a design type of","70":"is higher for carriers of","71":"have","72":"is a characteristic of","73":"demonstrate higher incidence of","74":"supports","75":"show promising effects of","76":"is a characteristic of","77":"is based on","78":"is caused by failure in","79":"is caused by failure in","80":"is part of","81":"is related to","82":"measures"},"weight_list":{"0":1.0,"1":1.0,"2":1.0,"3":1.0,"4":1.0,"5":1.0,"6":1.0,"7":1.0,"8":1.0,"9":1.0,"10":1.0,"11":1.0,"12":1.0,"13":1.0,"14":1.0,"15":1.0,"16":1.0,"17":1.0,"18":1.0,"19":1.0,"20":1.0,"21":1.0,"22":1.0,"23":1.0,"24":1.0,"25":1.0,"26":1.0,"27":1.0,"28":1.0,"29":1.0,"30":1.0,"31":1.0,"32":1.0,"33":1.0,"34":1.0,"35":1.0,"36":1.0,"37":1.0,"38":1.0,"39":1.0,"40":1.0,"41":1.0,"42":1.0,"43":1.0,"44":1.0,"45":1.0,"46":1.0,"47":1.0,"48":1.0,"49":1.0,"50":1.0,"51":1.0,"52":1.0,"53":1.0,"54":1.0,"55":1.0,"56":1.0,"57":1.0,"58":1.0,"59":1.0,"60":1.0,"61":1.0,"62":1.0,"63":1.0,"64":1.0,"65":1.0,"66":1.0,"67":1.0,"68":1.0,"69":1.0,"70":1.0,"71":1.0,"72":1.0,"73":1.0,"74":1.0,"75":1.0,"76":1.0,"77":1.0,"78":1.0,"79":1.0,"80":1.0,"81":1.0,"82":1.0}}